Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 170   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

 Table of Contents  
GUEST EDITORIAL
Year : 2014  |  Volume : 5  |  Issue : 1  |  Page : 2-3  

Pharmacovigilance: Curriculum and career


Senior Vice President and Chairman, Research and Development Core Committee, Cadila Pharmaceuticals Ltd., Dholka, Ahmedabad, Gujarat, India

Date of Web Publication13-Feb-2014

Correspondence Address:
Bhaswat S Chakraborty
Senior Vice President and Chairman, Research and Development Core Committee, Cadila Pharmaceuticals Ltd., Dholka, Ahmedabad, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2231-4040.126978

Rights and Permissions

How to cite this article:
Chakraborty BS. Pharmacovigilance: Curriculum and career. J Adv Pharm Technol Res 2014;5:2-3

How to cite this URL:
Chakraborty BS. Pharmacovigilance: Curriculum and career. J Adv Pharm Technol Res [serial online] 2014 [cited 2020 Oct 24];5:2-3. Available from: https://www.japtr.org/text.asp?2014/5/1/2/126978

Drug related deaths account for the fourth largest category of mortality in the United States. [1] In addition, in USA, estimated total cost of medication errors and adverse drug reactions (ADRs) exceed 136 billion dollars annually. [2] Although such accurate figures are not available for this category of mortality in India, a logical estimate may place drug related deaths very high in this country as well. This and this fact alone tell us that pharmacovigilance (PV) must be an integral part of the drug development during clinical trials and the actual use of the drug in patient population post marketing.

The World Health Organization (WHO) defines PV as the science and activities relating to the detection, evaluation, understanding and prevention of ADRs or any other drug-related problems. ADRs (especially the serious ones), medication and prescription errors and poor products qualities are the major reasons and areas of the practice of PV. Thus, risk management, risk mitigation plans and discovery of toxic signals from data mining of existing safety data bases are extremely important activities during both development and post approval phases in the life cycle of a drug. [3]

From 2007 onwards, both EMA and USFDA have empowered their agencies such that right now registration of any drug product in the USA and European countries is impossible without a thorough post marketing PV program (along with pre-marketing risk management plan). [4] An essential part of a proper PV program is also to maintain huge safety data bases. Such data bases often contain several million individual safety records of large pharmaceutical companies' marketed drugs, for example. Such requirements of maintaining very large data bases alone have prompted these firms to look for cost-effective PV set ups in economically emerging countries like India. Thus pharmaceutical MNCs require trained professionals for their PV data bases and related activities. The national PV programs as guided by WHO are also major hubs of PV activities wherein very specific and relevant curricular training and experience are required. It is interesting to note that the outsourced PV activities to India is on the rise for last 3 years or so even as the overall clinical trial activities coming to India are on a decline for the same period.

A career in PV requires adequate qualifications, proper training and also an employment which has both short and long term prospects. The basic qualifications for adapting to a PV career include undergraduate and/or graduate degrees in human and veterinary medicine, pharmacy, nursing or allied health sciences. Direct exposure to collection and organization of PV data, their processing and analyzes and further implications are required for anyone aspiring for such a career. There are at least half a dozen institutions in India where one can attend a course of duration of 1-2 years following graduation with an appropriate degree to get an initial orientation, exposure to some data and case studies and preparation for a real job. Needless to say, on the job training and experience offer the most significant portion of career motivation and insight.

The central theme in a PV career revolves around providing comprehensive medical, safety and analytical services. Such services include medical evaluation, assessment of expectedness and drug-ADR associations, casualty assessment, case narratives and processing, use of medical dictionaries, data mining and signal detection, medication error related activities and finally some specialized services. While the hard core knowledge base (e.g., medical or pharmacy) is essential, a good familiarity over data management, data base construction and data mining are additional huge assets in such careers. Specializations in PV include data collection and organization, safety administration and evaluation, regulatory submissions, data mining and unknown toxic signal identification etc.

Currently, pharmaceutical companies, CROs, IT firms, KPOs and consulting firms are the ones who are offering bulk of the PV positions as jobs in India. The regional PV centers and hospitals could be other major sources of finding the type of job being discussed here. These latter sources would not only provide some PV jobs, they can potentially open up a very caring side of the pharmacy and medical profession and reduce the gap between the taught syllabus and professional practice to serve the society.

 
  References Top

1.US FDA. ADRs: Prevalence and incidence. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm [Last accessed on 2014 Jan 20].  Back to cited text no. 1
    
2.Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.  Back to cited text no. 2
[PUBMED]    
3.Gavali DK, Kulkarni KS, Kumar A, Chakraborty BS. Therapeutic class-specific signal detection of bradycardia associated with propranolol hydrochloride. Indian J Pharmacol 2009;41:162-6.  Back to cited text no. 3
[PUBMED]  Medknow Journal  
4.Härmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.  Back to cited text no. 4
    

 
  Authors Top


Dr. Bhaswat S. Chakraborty




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References
   Authors

 Article Access Statistics
    Viewed2020    
    Printed53    
    Emailed1    
    PDF Downloaded312    
    Comments [Add]    

Recommend this journal